Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine

BMC Neurology

Volumn 4, Issue , 2004, Pages

  Krymchantowski, Abouch Valenty ^a,b,c   Bigal, Marcelo Eduardo ^d,e  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Instituto de Neurologia Deolindo Couto   (Brazil)

^c Headache Center of Rio   (Brazil)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIZATRIPTAN; ROFECOXIB; TOLFENAMIC ACID; ANTHRANILIC ACID DERIVATIVE; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN AGONIST; SULFONE; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAZIL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; NAUSEA; OPEN STUDY; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SOMNOLENCE; TACHYCARDIA; THORAX PAIN; ACUTE DISEASE; ADOLESCENT; DRUG COMBINATION; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; ORTHO-AMINOBENZOATES; RECURRENCE; SEROTONIN RECEPTOR AGONISTS; SULFONES; TREATMENT OUTCOME; TRIAZOLES; TRYPTAMINES;

EID: 12944270256     PISSN: 14712377     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2377-4-10     Document Type: Article

References (30)

1. Tfelt-Hansen P,: Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998, 18:532-538.
2. Solomon GD, Cady RK, Klapper JA, Early NL, Saper JR, Ramadan NM: Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997, 49:1219-1225.
3. Gobel G, Boswell D, Winter P, Crisp A: A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan. Cephalalgia 1997, 17:426-29.
4. Block GA, Goldstein J, Polis A, Reines SA, Smith ME: Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache 1998, 38:764-771.
5. Ferrari MD: Which Oral Triptan to Choose? In: Drug Treatment of Migraine and Other Headaches. Mongr Clin Neurosci Volume 17 Edited by: Diner HC. Basel: Karger; 2000:216-221.
6. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G: Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebocontrolled, outpatient study. Headache 1998, 38:281-287.
7. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH: Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Headache 1998, 38:748-755.
8. Gobel H, Petersen-Braun M, Heinze A: Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Frontiers in Headache Research. Headache Treatment: Trial Methodology and New Drugs Volume 6. Edited by: Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott-Raven; 1997:93-97.
9. Lipton RB, Stewart WF: Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999, 39(suppl 2):S20-S26.
10. Limmroth V, Przywara S: In: Drug Treatment of Migraine and Other Headaches. Mongr Clin Neurosci Volume 17. Edited by: Diner HC. Basel: Karger; 2000:30-43.
11. Krymchantowski AV, Barbosa JS, Cheim C, Alves L: Oral lysine clonixinate in the acute treatment of migraine. A double-blind placebo-controlled study. Arq Neuropsiquiatr 2001, 59(1): 46-49.
12. Tfelt-Hansen P, McEwen J: Nonsteroidal Antiinflammatory Drugs in the Acute Treatment of Migraine. In: The Headaches 2nd edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia: Lippincott-Raven; 2000:391-397.
13. Krymchantowski AV, Adriano M, Fernandes D: Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999, 19:186-7.
14. Krymchantowski AV: Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000, 58(2-B):428-430.
15. Krymchantowski AV, Barbosa JS: Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002, 22:309-312.
16. Masferrer JL, Isakson PC, Seibert K, Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996, 25(2):363-372.
17. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929-1933.
18. Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders. Cephalalgia 2004, 24:24-36.
19. Ferrari MD, Goadsby PJ, Room KI, Lipton RB: Triptans (Serotonin, 5HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002, 22(8 : 33-58.
20. Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P, Venkatraman S, Vrijens F, Malbecq W, Visser W, Reines S, Yuen E: A randomized, double-blind, placebo-controlled study of Rofecoxib 25 and 50 mg for the acute treatment of migraine. Neurology 2003, 60(suppl 1):A337 Abstract.
21. Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J: Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979, 2:326-328.
22. Parantainen J, Vapaatalo H, Hokkanen E: clinical aspects of prostaglandins and leukotrienes (LT) in migraine. Cephalalgia 1986, 6(suppl 4):95-101.
23. Sheftell F, Rapoport A, Weeks R, et al.: Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000, 40:158-63.
24. Saag K, Van Der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al.: Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal antiinflammatory drugs. Arch Fam Med 2000, 9(10 ):1124-34.
25. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, for the VIGOR study group, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with reumathoid arthritis. N Eng J Med 2000, 343:1520-8.
26. Mannix L, Von Seggern RL, Adelman JU: Rofecoxib for prevention of menstrual migraine: An open-label study. Neurology 2003, 60(suppl 1):A405 Abstract.
27. Myllyla V, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, Vapaatalo H, Eskerod O: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallelgroup study. Headache 1998, 38:201-7.
28. Bordini CA, Arruda MA, Cicciarelli MC, Speciali JG: Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiquiatr 1997, 55(3-B):536-541.
29. Peroutka SJ: Beyond monotherapy: Rational polytherapy in migraine. Headache 1998, 38:18-22.
30. Pascual J, Leira R, Lainez JM: Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus Valproate in 52 resistant migraine patients. Headache 2003, 43:586 Abstract.